^
    7ms
    Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov)
    P1, N=81, Active, not recruiting, AbbVie | Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024
    Trial completion date • Trial primary completion date • Adverse events • Combination therapy
    |
    EGFR expression • EGFR wild-type
    |
    Tagrisso (osimertinib) • docetaxel • ABBV-637
    10ms
    First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC) (ESMO 2023)
    Conclusions ABBV-637 plus OSI showed clinical activity and a manageable safety profile in patients with RR NSCLC. Biomarker data suggest that response to ABBV-637 plus OSI may be enriched by excluding patients with targetable bypass mechanisms; ongoing research is needed to confirm association of mutation and patient selection.
    P1 data
    |
    BCL2L1 (BCL2-like 1)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • ABBV-637
    12ms
    Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov)
    P1, N=81, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Nov 2023 | Trial primary completion date: Nov 2026 --> Nov 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Adverse events • Combination therapy
    |
    EGFR expression • EGFR wild-type
    |
    Tagrisso (osimertinib) • docetaxel • ABBV-637
    over2years
    Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov)
    P1, N=109, Recruiting, AbbVie | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial primary completion date • Adverse events • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Tagrisso (osimertinib) • docetaxel • ABBV-637
    almost3years
    Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov)
    P1, N=109, Recruiting, AbbVie | N=60 --> 109 | Trial completion date: Nov 2025 --> Nov 2026
    Clinical • Enrollment change • Trial completion date • Adverse events • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Tagrisso (osimertinib) • docetaxel • ABBV-637
    over3years
    Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, AbbVie
    Clinical • New P1 trial • Adverse events • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Tagrisso (osimertinib) • docetaxel • ABBV-637